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Abstract
Metabolic reprogramming of tumor cells involves upregulation of fatty acid (FA) synthesis to support high bioenergetic 
demands and membrane synthesis. This has been shown for cytosolic synthesis of FAs with up to 16 carbon atoms. Synthesis 
of long-chain fatty acids (LCFAs), including ω-6 and ω-3 polyunsaturated FAs, takes place at the endoplasmic reticulum. 
Despite increasing evidence for an important role of LCFAs in cancer, the impact of their synthesis in cancer cell growth has 
scarcely been studied. Here, we demonstrated that silencing of 17β-hydroxysteroid dehydrogenase type 12 (17β-HSD12), 
essentially catalyzing the 3-ketoacyl-CoA reduction step in LCFA production, modulates proliferation and migration of breast 
cancer cells in a cell line-dependent manner. Increased proliferation and migration after 17β-HSD12 knockdown were partly 
mediated by metabolism of arachidonic acid towards COX2 and CYP1B1-derived eicosanoids. Decreased proliferation was 
rescued by increased glucose concentration and was preceded by reduced ATP production through oxidative phosphoryla-
tion and spare respiratory capacity. In addition, 17β-HSD12 silencing was accompanied by alterations in unfolded protein 
response, including a decrease in CHOP expression and increase in eIF2α activation and the folding chaperone ERp44. Our 
study highlights the significance of LCFA biosynthesis for tumor cell physiology and unveils unknown aspects of breast 
cancer cell heterogeneity.
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Introduction
Fatty acids (FAs) serve as energy source, act as signaling 
molecules, and are essential structural elements of the lipid 
bilayer, where they can be found in esterified form in phos-
pholipids. The wide spectrum of FAs results from elonga-
tion of shorter precursors, through sequential addition of two 
carbon atoms, provided by malonyl-CoA. Production of FAs 
with carbon chain length up to 16 takes place in the cytosol, 
through a four-step process performed by the multi-activity 
enzyme fatty acid synthase (FASN) [1]. Long-chain fatty 
acids (LCFAs) containing more than 18 carbon atoms are 
produced in a similar fashion by four different endoplasmic 
reticulum (ER) enzymatic entities; the elongases of LCFAs 
(ELOVL1–7), 3-ketoacyl-CoA reductase (KAR) (also 
known as 17β-hydroxysteroid dehydrogenase type 12, 17β-
HSD12 or SDR12C1), 3-hydroxyacyl-CoA dehydratases 
(HACD1–4) and 2,3-trans-enoyl-CoA reductase (TER) 
(Fig. 1a) [2]. FA elongation combined with desaturation 
leads to a multitude of distinct FAs with unique molecular 
properties and cellular functions.
De novo FA synthesis mainly occurs in tissues with high 
lipogenic activity, including the liver and adipose tissue. 
Nevertheless, glucose can be readily utilized by tumor cells 
for FA synthesis, and it was shown that the rate of lipogene-
sis in mouse hepatoma is comparable to that in non-neoplas-
tic liver tissue [3]. An upregulation of de novo FA synthesis 
is generally accepted to have a major role in the metabolic 
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Fig. 1  Effect of 17β-HSD12 on cancer cell proliferation. a Every 
elongation round of LCFAs consists of four steps. During the first 
step, the elongases of very long-chain fatty acids (ELOVL1–7) con-
dense malonyl-CoA with a substrate fatty acyl-CoA. Subsequently, 
3-ketoacyl-CoA reductase (KAR or 17β-HSD12) reduces the 3-ketoa-
cyl-CoA to 3-hydroxyacyl-CoA, which is then subjected to dehydra-
tion by 3-hydroxyacyl-CoA dehydratases (HACD1–4). A final reduc-
tion step is performed by 2,3-trans-enoyl-CoA reductase (TER) to 
yield a fatty acyl-CoA elongated by two carbon atoms. b The essen-
tial PUFAs linoleic acid and α-linolenic acid give rise to a wide array 
of ω-6 and ω-3 FAs, respectively, through a series of elongation and/
or desaturation reactions. Fatty acid desaturases (FADS1 and FADS2) 
and ELOVLs (ELOVL2 and ELOVL5) with distinct substrate pref-
erences participate at different steps of this metabolic pathway. The 
ω-6 osbond acid (22:5) and ω-3 docosahexaenoic acid (DHA, 22:6) 
are produced via elongation and desaturation of docosatetraenoic 
acid (DTA) and docosapentaenoic acid (DPA), respectively, followed 
by β-oxidation in peroxisomes. c MCF7, MDA-MB-453, SUM159, 
and MDA-MB-231 cells were transfected with mock or 17β-HSD12 
siRNA or left untreated (ctrl). (Left panel) Live measurements of 
cell proliferation were performed with the xCELLigence RTCA DP 
instrument. The cell index values (average and standard deviation of 
four technical replicates) from one out of three independent experi-
ments are shown. For the SUM159 cells, the cell index was normal-
ized to 5 h to account for small differences in seeding in this experi-
ment. (Right panel) At 24  h, 48  h, and 72  h post-transfection with 
siRNAs, cell nuclei were stained with Hoechst-33342 and analyzed 
by high-content imaging. The values represent the mean and error 
bars SD from at least three independent experiments per cell line, 
and are normalized to the mock siRNA samples at each time point 
(*p < 0.05, ***p < 0.001, ns not significant)
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rewiring of cancer cells [4–6]. FASN is abundantly present 
in human tumors, including breast cancer [7], and has been 
the focus of numerous anti-cancer therapeutic attempts [8]. 
Several other enzymes involved in FA biosynthesis and its 
regulation are overexpressed or overactivated in malignant 
tissues [9].
The role of cytosolic FA synthesis in cancer is a field of 
intense research; in contrast, de novo synthesis of LCFAs 
has received less attention. Saturated and monounsaturated 
LCFAs derive from elongation of palmitic acid, whereas 
polyunsaturated fatty acids (PUFAs) originate from two 
essential FAs, the linoleic acid (LA, C18:2) and α-linolenic 
acid (ALA, C18:3) that generate the ω-6 and ω-3 FA series, 
respectively [10] (Fig. 1b). ω-6 PUFAs have a double bond 
at position 6, when counting as 1 the carbon atom opposite 
of the carboxylic group, whereas ω-3 PUFAs have a double 
bond at the corresponding position 3. PUFAs with well-
established physiological functions include the ω-6 arachi-
donic acid (AA) and the ω-3 docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA). Metabolism of AA gives 
rise to key pro-inflammatory eicosanoids, including prosta-
glandins and leukotrienes, which support immune system 
evasion and promote tumor cell proliferation and angiogen-
esis [11, 12]. On the other hand, DHA and EPA give rise to 
metabolites that dampen inflammatory response and limit 
malignant cell growth [13]. In many tumors, the ratio of 
ω-6/ω-3 PUFAs has been reported to be elevated compared 
to adjacent non-cancerous tissue [14–16]. Several epidemio-
logical studies found a positive correlation between con-
sumption of ω-3 PUFAs and reduced cancer risk [17–19]. 
Based on this, a wealth of in vitro, animal and clinical stud-
ies have aimed at evaluating the potential benefits of ω-3 
PUFA preventive supplementation or utilization as adjuvant 
antineoplastic therapy [20]. Despite some promising results, 
so far findings have not led to definitive conclusions. This 
could be partially attributed to inter-individual differences 
in the metabolism of diet-supplemented FAs, including the 
expression and activity of the involved enzymes. Moreo-
ver, the possible significance of de novo biosynthesis and 
metabolism of LCFAs has been scarcely explored.
Interestingly, in two earlier reports, silencing of 17β-
HSD12 expression, the enzyme performing the first reduc-
tion step in LCFA elongation (Fig. 1a), in one breast can-
cer and one ovarian cell line led to decreased proliferation, 
which could be reverted by AA supplementation [21, 22]. 
These and one additional study found a correlation between 
high 17β-HSD12 expression and poor prognosis for survival 
in patients with breast and ovarian tumors [23]. In contrast, 
knockdown of 17β-HSD12 in mammary epithelial cells was 
shown to promote cell proliferation, whereas overexpression 
of the enzyme led to the opposite effect [24]. Recently, an 
elaborate transcriptomic study of 17 different cancer types in 
a total of around 8000 patients was performed, with data of 
the Cancer Genome Atlas and Human protein Atlas Projects. 
This analysis showed that 17β-HSD12, along with other 
genes involved in the elongation and desaturation of LCFAs, 
correlates with either good or poor prognosis, depending on 
the tumor type [25]. Importantly, 17β-HSD12 was identified 
as a prognostic gene for favorable outcome in renal cancer 
and unfavorable in liver cancer patients. Thus, the role of 
LCFA synthesis in cancer, including that of 17β-HSD12, 
is insufficiently understood and deserves further research.
In the current study, we addressed the importance of this 
biosynthetic pathway by analyzing the consequences of 
17β-HSD12 silencing in different breast cancer cell lines. 
This model is particularly interesting, given the heteroge-
neous molecular profile of breast tumor cells. We analyzed 
the impact of 17β-HSD12 downregulation on cell prolif-
eration, migration, and energy metabolism. In addition, we 
explored whether inhibition of LCFA synthesis at the ER 
could constitute a stress signal for transformed cells, lead-
ing to changes in the unfolded protein response (UPR). Our 
results show that silencing 17β-HSD12 expression has diver-
gent outcomes in cell survival and invasiveness in different 
cell lines, and leads to a number of alterations in cancer 
cell physiology, including energy source utilization. This 
study contributes to the understanding of how the biosyn-
thetic pathway for LCFAs affects homeostasis of malignant 
cells, which is a necessary step for evaluating the clinical rel-
evance of ω-3 and ω-6 PUFAs for cancer patient treatment.
Materials and methods
Chemicals and reagents
Trifluoromethoxy carbonyl cyanide phenylhydrazone 
(FCCP), AA, DHA, EPA, thioridazine (Thio), and 
2,3′,4,5′-tetramethoxystilbene (TMS) were purchased from 
Cayman Chemical (Ann Arbor, MI, USA). All other com-
pounds and reagents were purchased from Sigma-Aldrich 
(Buchs, Switzerland), unless otherwise specified.
Cell culture and treatments
All cell lines were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) and cul-
tured at 37 °C and 5%  CO2. SUM159 cells were cultured 
in Ham’s F12 nutrient mixture (Thermo Fisher Scientific, 
Waltham, MA USA), supplemented with 5% fetal bovine 
serum (FBS) and 5 μg/ml bovine pancreas insulin. MCF7 
cells were grown in Dulbecco’s Modified Eagle’s medium 
(DMEM) containing 4.5 g/l glucose, 10% FBS, and nones-
sential amino acid mixture. For the growth of MDA-MB-453 
and MDA-MB-231 cells, RPMI 1640 medium supplemented 
with 10% FBS was used. This medium was also used in 
1156 M. Tsachaki et al.
1 3
certain experiments with SUM159 cells. For the experiments 
with different glucose concentrations, RPMI 1640 without 
glucose (Thermo Fisher Scientific, #11879020) was supple-
mented with 4 g/l, 2 g/l, or 0.5 g/l glucose. For the experi-
ments to assess the possible effects of glutamine, RPMI 
1640 without glutamine (Bioconcept Ltd., Allschwil, Swit-
zerland, #1-41F01-I) was supplemented or not with 2 mM 
glutamine. In all culture media, 10 mM HEPES buffer pH 
7.4 and a mixture of 100 U/ml penicillin/100 μg/ml strepto-
mycin (BioConcept Ltd.) were added.
For transfection of cells with siRNAs, Lipofectamine 
RNAiMax (Thermo Fisher Scientific) was used. Reverse 
transfection was performed, with the seeding of cells and 
siRNA transfection taking place simultaneously. Per 100,000 
cells, 20 pmol siRNA and 1 μl lipofectamine reagent was 
used. The target sequences recognized by the siRNAs are: 
mock (scrambled) 5′-UGG UUU ACA UGU UUU CUG A-3′, 
HSD17B12 5′-GAA CUA AUA UUG UCG GGA A-3′ (‘siR-
NA1’-used throughout the study), HSD17B12 5′-GAA AUC 
GGC AUC UUA GUG A-3′ (‘siRNA2’), HSD17B12 5′-UAA 
GAU GAC ACA AUU GGU A-3′ (‘siRNA3’), eIF2α 5′-GUA 
CAA GAG ACC UGG AUA UTT-3′ and RXRα 5′-AGG 
ACU GCC UGA UUG ACA ATT-3′ (Microsynth AG, Bal-
gach, Switzerland).
In all cell treatments where compound stock solutions 
were dissolved in DMSO, the final concentration of the latter 
did not exceed 0.02%. For FA supplementation, 8 mM FAs 
were conjugated with 10% FA-free BSA after incubation for 
1 h at 37 °C, prior to addition to the cell culture medium.
Proliferation measurements with the real‑time cell 
analyzer (RTCA)
Cell proliferation in real time was monitored using the 
xCELLigence RTCA DP instrument (ACEA Biosciences, 
Inc., San Diego, CA, USA). 5000 SUM159, 7500 MCF7, 
10,000 MDA-MB-453, or 15,000 MDA-MB-231 cells were 
reverse transfected with siRNAs or left untreated and seeded 
on an E-plate View 16. Quadruplets of all samples were pre-
pared and impedance signals were measured every 30 min 
for 96 h. Data were analyzed using the RTCA 2.0 software.
Assessment of cell number by high‑content imaging
For estimation of the cell number at different time points 
on 96-well plates, we fixed cells with 4% formaldehyde and 
stained nuclei with 5 μg/ml Hoechst-33342 (Thermo Fis-
cher Scientific). Counting of stained nuclei was performed in 
high throughput with the  ArrayScan® high-content imaging 
system (Thermo Fischer Scientific), according to a proto-
col adjusted for each cell line. In every experiment, each 
sample was represented by six technical replicates (different 
wells) and 14 fields were randomly chosen in each well for 
counting.
BrdU cell proliferation assay
To assess cell proliferation, we seeded 5000 SUM159 or 
7500 MDA-MB-231 cells in 96-well plates and performed 
reverse transfection with siRNAs as described above. 
After 48 h, the conditioned medium was replaced by fresh 
medium-containing 10 μΜ BrdU for 2.5 h. Cells were sub-
sequently washed twice with PBS, fixed with 4% formal-
dehyde, washed three times with PBS, and permeabilized 
with 0.2% Triton for 5 min. After three washes with PBS, 
DNA was denatured with 2 N HCl for 30 min, and cells 
were washed three times with PBS and once with PBS gly-
cine (0.75% w/v glycine in PBS). After incubation with PBS 
glycine for 30 min and blocking with 1% BSA for 30 min, 
rat monoclonal antibody against BrdU was added (Abcam, 
Cambridge, UK, Ab6326) in a dilution of 1:360 in 1% BSA. 
Following three washes with PBS, goat anti-rat IgG Alexa 
Fluor 555 (Thermo Fischer Scientific) was added in a dilu-
tion of 1:360 along with 5 μg/ml Hoechst and incubated for 
40 min. Cells were washed four times with PBS and cells 
positive for BrdU staining counted with the  ArrayScan® 
high-content imaging system (Thermo Fischer Scientific), 
using the BGRFR_386_23 and BGRFR_659_15 filters for 
detection of cell nuclei and BrdU-positive cells, respectively.
Migration and adhesion assays
To assess migration potential, cells were transfected with 
siRNAs and seeded on a 35 mm dish. At 48 h post-trans-
fection, cells were reseeded on a trans-well insert (diam-
eter 6.5 mm, pore size 8 µm; Corning Inc., Lowell, MA, 
USA). The cell numbers seeded were 7500 for SUM159, 
20,000 for MCF7, 30,000 for MDA-MB-453 and 15,000 for 
MDA-MB-231 cells. The cells were allowed to migrate for 
24 h from medium-containing 1% FBS for SUM159 and 
MDA-MB-231 or 0.5% FBS for MCF7 and MDA-MB-453 
cells towards medium-containing 10% FBS. Subsequently, 
cells were stained with 0.1% crystal violet (w/v in 25% 
methanol). After removal of the cells at the top chamber, 
migrated cells were visualized under the 20 × objective of 
a light microscope (Zeiss Axiovert 100; Carl Zeiss Micros-
copy GmbH, Feldbach, Switzerland). Images were captured 
from ten fields using a digital camera (EOS 70D, Canon, 
Tokyo, Japan) and cells counted with the ImageJ software 
(National Institute of Health, MD, USA). For the experi-
ments where glutamine was assessed, 48 h after siRNA 
transfection, 40,000 MDA-MB-231 cells were seeded on 
a CIM-Plate 16 (ACEA Biosciences Inc.) and migration 
was measured over a period of 24 h using the xCELLigence 
RTCA DP instrument.
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Cell adhesion assays were performed essentially as elabo-
rated in Ref. [26].
Quantitative polymerase chain reaction (qPCR)
Evaluation of mRNA abundance was performed by qPCR 
as described previously [26]. The sequences of the primers 
used are shown in Table 1.
Western blotting
Cell lysis and sample preparation for western blot have been 
described before [27]. The antibodies used for detection of 
specific proteins and their final concentrations in 5% defatted 
milk blocking solution were the following.
17β-HSD12 0.05 μg/ml (SIGMA-Aldrich HPA016427), 
α-tubulin 0.062  μg/ml (GeneTex, Irvine, CA, USA, 
#GTX628802), actin 0.67 μg/ml (Santa Cruz Biotechnol-
ogy, sc-1616), PPIA 0.05 μg/ml (Abcam, Ab41684), PERK 
0.1 μg/ml (Cell signaling Technology, Danvers, MA, USA, 
#3192), eIF2α 0.1  μg/ml (Cell Signaling Technology, 
#9722S), peIF2α 0.3 μg/ml (Cell Signaling Technology, 
#119A11), ATF4 0.1 μg/ml (Cell Signaling Technology, 
#11815S), ATF6 0.25 μg/ml (Cell Signaling Technology, 
#65880S), CHOP 1.2 μg/ml (Cell Signaling Technology, 
#2895S), sXBP1 0.1 μg/ml (Cell Signaling Technology, 
#12782S), GRP78 0.62 μg/ml (BD Bioscience, San Jose, 
CA, USA, #610978), ERp44 1:1000 dilution [26], PDI 
0.1  μg/ml (Abcam, Cambridge, UK, Ab2792), ERp72 
1:1000 dilution (Stressgen), GRP94 1:1000 dilution [28], 
FADS1 0.5 μg/ml (Santa Cruz Biotechnology, sc-134337), 
FADS2 0.5 μg/ml (Abcam, ab72189), G6PD 1 μg/ml (Bethyl 
Laboratories, TX, USA, A300-404A), PGD 1:1000 (Abcam, 
ab129199) and RXRα 0.1 μg/ml (Santa Cruz Biotechnology, 
sc-515929), Akt 0.1 μg/ml (Abcam, ab126811), pAkt Ser473 
0.1 μg/ml (Cell Signaling Technology, #9271), Caspase-9 
(Cas-9)/cleaved Cas-9 0.1 μg/ml (Cell Signaling Technol-
ogy, #9508), Caspase-3 (Cas-3) 0.1 μg/ml (Cell Signaling 
Technology, #9665), cleaved Cas-3 0.1 μg/ml (Cell Signal-
ing Technology, #9664), Bcl-2 0.1 μg/ml (Cell Signaling 
Technology, #2870), Bax 0.1 μg/ml (Cell Signaling Technol-
ogy, #5023), and ELOVL5 1 μg/ml (Origene, #TA315700). 
Samples were not boiled for detection of ELOVL5, due to 
the protein aggregation occurring otherwise. The signal den-
sity of protein bands was measured using the ROI manager 
tool of ImageJ. For relative protein-level quantification, the 
density of each band was compared to that of the loading 
control (actin, α-tubulin or PPIA) in every lane. Different 
loading controls were used depending on the size of the 
proteins of interest and the species origin of the primary 
antibody.
Immunofluorescence staining and microscopy
Indirect immunofluorescence staining has been described 
earlier [26]. Visualization of the fluorescence signal and 
image acquisition was performed utilizing the 20 × objective 
Table 1  Oligonucleotide 
primers used for qPCR
Gene name Sense/antisense primers (5′–3′)
PPIA ATG GTC AAC CCC ACC GTG T/TCT GCT GTC TTT GGG ACC TTGTC 
MMP1 GCA CAA ATC CCT TCT ACC CG/TGA ACA GCC CAG TAC TTA TTCC 
MMP2 ACC CAT TTA CAC CTA CAC CAAG/TGT TTG CAG ATC TCA GGA GTG 
MMP14 TGC CTA CCG ACA AGA TTG ATG/ATC CCT TCC CAG ACT TTG ATG 
Vim ACC CTG CAA TCT TTC AGA CAG/GAT TCC ACT TTG CGT TCA AGG 
CTNNB1 (β-cat) GTT CAG TTG CTT GTT CGT GC/GTT GTG AAC ATC CCG AGC TAG 
CHOP GTA CCT ATG TTT CAC CTC CTGG/TGG AAT CTG GAG AGT GAG GG
ERp44 AAC CGG AAA GAT ATA GTG GCG/TCG GAC AAG AGG AAC ACA TTT 
HSD17B12 GAA CAT TTC ATC TGG CAG TGG/GAA GTA TGG CAG GAC ACT CTG 
ELOVL5 AAC CTT GGA CTC ACA CTG C/CAC CAG AGG ACA CGG ATA ATC 
ELOVL7 GCC AGC CTA CCA GAA GTA TTTG/CAC GCA AAG ACT GGA AAC TG
ELOVL2#1 CAT CTA TGC ACA AGT ATC TTT GGT G/GGA AGA TGA GAC AAC CGA AGG 
ELOVL2#2 GGA GGC TAC AAC TTA CAG TGTC/CCA GGA ACT CTA CTG ATT TGGAG 
FADS1 GTA CAA CCA CCA GCA CAA ATAC/GAA GCG GAC GTA GAA GGT AATC 
FADS2 TGT CTA CAG AAA ACC CAA GTGG/TGT GGA AGA TGT TAG GCT TGG 
RXRα CCA TCG TCC TCT TTA ACC CTG/AGC AAG AGC TTA GCG AAC C
CYP1B1 CTA TCA CTG ACA TCT TCG GCG/CAT ACA AGG CAG ACG GTC C
CYP4V2 GGC TTG ATC TCT GGT ACC TTATG/GCC ATC ACC TCT ACA GTC TTC 
PTGER2 CCT CAT TCT CCT GGC TAT CATG/CTT TCG GGA AGA GGT TTC ATTC 
GADD34 GAA ACC CCT ACT CAT GAT CCG/AAA TGG ACA GTG ACC TTC TCG 
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of a DMI4000 B Microscope (Leica Microsystems, Wetzlar, 
Germany) and processed with the ImageJ software.
Seahorse XF Cell Mito Stress Test
Measurements of oxygen consumption rate (OCR) and extra-
cellular acidification rate (ECAR) were performed in real 
time with the Seahorse XF96 analyzer (Agilent Technolo-
gies, CA, USA). The different parameters of mitochondrial 
respiration were evaluated using the Seahorse XF Cell Mito 
Stress Test, according to the manufacturer’s instructions. 
Cells were transfected 48 h prior to the assays with siRNAs 
and seeded in six replicates per sample on a Seahorse XF96 
V3 PS Cell Culture Microplate (Agilent Technologies). In 
this assay, baseline cellular OCR was measured, represent-
ing both mitochondrial and non-mitochondrial respiration 
(Suppl. Figure 7a). The proportion of mitochondrial OCR 
linked with ATP production is measured after addition 
of the ATPase inhibitor oligomycin at a concentration of 
1 μΜ. Subsequently, 0.5 μM of the uncoupling agent FCCP 
is added, which collapses the electron gradient across the 
mitochondrial membrane and leads to a compensatory maxi-
mal oxygen consumption from the mitochondria, thereby 
enabling measurement of maximal respiration. The spare 
respiratory capacity is calculated by deduction of the basal 
mitochondrial respiration from this value. Finally, a mixture 
of 0.5 μM of antimycin and 0.5 μM rotenone is added, inhib-
iting function of complex III and I, and thus, completely 
shutting down mitochondrial oxygen consumption. This 
allows for calculation of non-mitochondrial OCR. Deduction 
of this value from that obtained after oligomycin treatment 
yields the portion of OCR resulting from proton leak. Basal 
respiration is the initial OCR value excluding non-mitochon-
drial respiration. Eto or Thio was added at a concentration 
of 40 μΜ 15 min prior to the commencement of the assay. 
Following the measurements, values were normalized to the 
protein content of each sample using the Pierce™ BCA Pro-
tein Assay Kit (Thermo Fisher Scientific, MA, USA). Data 
were analyzed employing the Wave 2.6.0 software.
Quantification of AA
To quantify AA in cells, the competitive AA ELISA assay 
was used (OKEH02583, Aviva Systems Biology, CA, USA), 
in line with the manufacturer’s guidelines. AA was meas-
ured in transfected cells 48 h post-siRNA delivery. Cells 
were subjected to five freeze/thaw cycles to break up cell 
membranes, and samples were centrifuged for 20 min at 
1200g, 4 °C. Subsequently, the supernatant was collected 
and assayed on the ELISA plate. The amount of AA was 
calculated based on the standard curve of serially diluted 
standards provided with the kit. To normalize to the protein 
content of each sample, the Pierce™ BCA Protein Assay 
was employed.
Quantitative and statistical analysis
All experiments in this study were performed at least three 
times independently and values shown in graphs are the 
mean of these experiments (with the exception of xCEL-
Ligence experiments where a representative measurement is 
shown in Fig. 1c). Error bars represent standard deviations 
(SD). Statistical significance of the difference between con-
ditions was calculated with a two-tailed Student’s t test. The 
levels of significance are as follows: *p < 0.05, **p < 0.01, 
and ***p < 0.001.
Results
Effect of 17β‑HSD12 downregulation on breast 
cancer cell proliferation and migration
To assess the impact of 17β-HSD12 on proliferation and 
migratory potential of tumor cells, we used four breast can-
cer cell lines, each representing one of the three main molec-
ular subtypes of breast cancer; the MCF7 that is positive 
for the estrogen receptor-α (ER) and progesterone receptor 
(PR) but negative for the human epidermal growth factor 
receptor 2 (HER2), the MDA-MB-453 that is negative for 
ER and PR but positive for HER2, and the SUM159 and 
MDA-MB-231 that are triple-negative  (ER−,  PR−,  HER2−). 
First, we evaluated the efficiency of siRNA knockdown 
over time (24 h, 48 h, and 72 h) in all cell lines by west-
ern blot, using a specific antibody against 17β-HSD12. In 
all cases, we found a time-dependent decrease in protein 
levels after siRNA transfection compared to mock- and 
non-transfected cells (Suppl. Figure 1). Next, we tested the 
effect of 17β-HSD12 downregulation on cell proliferation 
with live measurements up to 96 h after siRNA transfec-
tion using the xCELLigence RTCA (Fig. 1c, left panel). 
In parallel, we performed endpoint measurements of cell 
numbers at 24 h, 48 h, and 72 h, by Hoechst-33342 staining 
of nuclei and high-content imaging analysis (Fig. 1c, right 
panel). The results from both approaches were in accord-
ance. Downregulation of 17β-HSD12 led to decreased pro-
liferation of SUM159 cells and increased proliferation of 
MCF7, MDA-MB-453 and MDA-MB-231 cells. The time 
after knockdown when differences in proliferation were sta-
tistically significant varied, which can partly be attributed 
to the different growth rates among cell lines. To validate 
the specificity of the siRNA against 17β-HSD12 used in 
the above experiments (‘siRNA1’), we employed two addi-
tional siRNAs (‘siRNA2’ and ‘siRNA3’) in experiments 
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with Hoechst-33342 staining and high-content imaging for 
the SUM159 and MDA-MB-231 cells and obtained similar 
results (Suppl. Figure 2).
Subsequently, we explored whether the reduction in cell 
number following 17β-HSD12 knockdown in SUM159 cells 
could be due to increased apoptosis. We found unchanged 
ratios of cleaved Cas-9/Cas-9, as well as cleaved Cas-3/
Cas-3 at 48 h post-transfection with 17β-HSD12 siRNA 
(Suppl. Figure 3a). In addition, the ratio of the apoptosis 
regulators Bax/Bcl-2, which is used as an indicator of apop-
totic levels, was not altered (Suppl. Figure 3a). Moreover, 
we examined whether ferroptosis, a non-apoptotic form of 
cell death involving iron-dependent accumulation of lipid 
reactive oxygen species, could contribute to the reduced cell 
number after 17β-HSD12 downregulation in SUM159 cells. 
For this purpose, we treated cells with 1 μΜ of the ferropto-
sis inhibitor ferrostatin and knocked-down 17β-HSD12. Our 
data showed a significant reduction in cell number upon fer-
rostatin treatment, as observed in the absence of the inhibitor 
(Suppl. Figure 3b). Taken together, the above results do not 
support an involvement of apoptosis or ferroptosis as mecha-
nisms implicated in the 17β-HSD12-knockdown phenotype 
in SUM159 cells.
We then examined the impact of 17β-HSD12 knockdown 
on cell migration using the trans-well migration assay with 
serum as an attractant to promote cell mobility (Fig. 2a). 
We observed that MCF7 and MDA-MB-231 cells exhib-
ited increased migratory capacity upon 17β-HSD12 silenc-
ing, whereas SUM159 cells displayed a decrease. These 
results follow the behavior of the proliferation phenotype 
of 17β-HSD12-knockdown cells. However, MDA-MB-453 
cells showed higher proliferation after 17β-HSD12 down-
regulation, but decreased migration. Since this cell line is 
hardly invasive (four times more cells than those seeded 
for the SUM159 cells and lower FBS concentration in the 
top chamber were used in the assay), the physiological rel-
evance of this result is unclear. Given that the cell cytoskel-
eton constitutes a major component of cell motility, we then 
investigated whether the observed alterations in cell migra-
tion are reflected in the subcellular architecture of two vital 
cytoskeletal elements; actin filaments and microtubules. 
For these experiments, we compared SUM159 and MDA-
MB-231 cells and observed a decrease and increase, respec-
tively, in cell growth and migration following 17β-HSD12 
knockdown. Immunofluorescence staining with phalloidin-
FITC showed that the actin cytoskeleton outlines cells with 
less elongated and smoother morphology after 17β-HSD12 
downregulation in MDA-MB-231 cells, whereas no dif-
ference was observed in SUM159 cells (Suppl. Figure 4). 
However, staining of microtubules with an antibody against 
Fig. 2  Impact of 17β-HSD12 silencing on cancer cell migration and 
adhesion. a Trans-well migration assays for MCF7, MDA-MB-453, 
SUM159, and MDA-MB-231 cells after transfection with mock or 
17β-HSD12 siRNAs. The absolute values of migrated cells counted 
are shown (mean ± SD, n = 3, *p < 0.05, **p < 0.01). b (top) Rela-
tive mRNA levels of the indicated genes measured with qPCR 48 h 
after 17β-HSD12 downregulation in SUM159 or MDA-MB-231 cells 
(mean ± SD, n = 4, *p < 0.05, ns not significant) (bottom). The ability 
of SUM159 or MDA-MB-231 cells to adhere to plates, with or with-
out fibronectin coating, was tested in mock- or 17β-HSD12-siRNA-
transfected cells (mean ± SD, n = 6, ns not significant)
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α-tubulin in SUM159 cells showed that 17β-HSD12 silenc-
ing caused redistribution of the microtubular network 
around the nucleus (Suppl. Figure 5). No obvious differ-
ence in α-tubulin pattern was observed between mock- and 
17β-HSD12-siRNA-transfected MDA-MB-231 cells.
We further investigated the changes accompanying the 
altered migration in SUM159 and MDA-MB-231 cells 
after 17β-HSD12 knockdown. Specifically, we analyzed the 
mRNA expression levels of genes involved in cell migration 
and adhesion during cancer metastasis. In SUM159 cells, 
an increase in matrix metalloproteinase 2 (MMP2) was 
observed after 17β-HSD12 silencing (Fig. 2b). Although no 
expression of MMP2 could be detected in MDA-MB-231 
cells, 17β-HSD12 knockdown led to decreased expres-
sion of MMP1 and of the intermediate filament protein 
vimentin (VIM). One would expect that these changes lead 
to decreased adhesion in SUM159 cells due to increased 
MMP2 levels and increased adhesion in MDA-MB-231 
cells due to decreased MMP1 and VIM levels. However, 
in cell adhesion assays using fibronectin-coated dishes, no 
difference in cell adhesion was observed after 17β-HSD12 
downregulation in neither cell line (Fig. 2b).
Investigation of the differential impact 
of 17β‑HSD12 on proliferation and migration 
of SUM159 and MDA‑MB‑231 cells
We next addressed the underlying reason for the diverse 
phenotypes observed after 17β-HSD12 downregulation. 
To compare closely related cell systems, we used SUM159 
and MDA-MB-231 cells. Interestingly, despite both being 
triple-negative breast cancer cell lines, SUM159 and MDA-
MB-231 cells exhibited decreased and increased cell prolif-
eration and migration, respectively, after 17β-HSD12 knock-
down. Since 17β-HSD12 is involved in LCFA synthesis, we 
reasoned that the difference could lie in the availability of 
precursors in the culture medium. Of note, the Ham’s F-12 
nutrient mixture (hereinafter F-12), used to culture SUM159 
cells, contains the AA precursor linoleic acid, which is not 
present in the RPMI 1640 medium for MDA-MB-231 cells. 
This could mean that in SUM159 cells, 17β-HSD12 actively 
produces AA, which, as mentioned above, has been shown to 
promote cell growth and invasion. In this case, knockdown 
of 17β-HSD12 would lead to the observed reduction of cell 
growth and migratory potential, because of reduced AA pro-
duction. In contrast to our hypothesis, culturing SUM159 
cells in the RPMI 1640 medium neither altered the effect of 
17β-HSD12 downregulation on cell number nor migration 
(Fig. 3a), suggesting that the culture medium is not respon-
sible for the distinct phenotypes after 17β-HSD12 silencing 
in SUM159 and MDA-MB-231 cells. For culturing SUM159 
cells, the F-12 medium is also supplemented with insulin 
[29]. However, supplementation of RPMI 1640 with insulin 
did not change the 17β-HSD12-knockdown effect on cell 
proliferation.
After excluding the culture medium as a determining 
factor, we compared the expression in the two cell lines 
of the different ELOVL enzymes (ELOVL2, ELOVL5, 
and ELOVL7) and the fatty acid desaturases (FADS1 and 
FADS2), since these enzymes preferentially catalyze distinct 
steps during PUFA biosynthesis (Fig. 1b). We observed that 
the mRNA and protein expression of ELOVL5 was signifi-
cantly lower in the SUM159 cells (Fig. 3b, c). Although 
FADS2 mRNA levels were higher in MDA-MB-231 com-
pared to SUM159 cells, protein expression was comparable 
in both cell lines (Fig. 3b, c). The mRNA of ELOVL7 that 
is also able to elongate certain LCFAs in a tissue-restricted 
manner is present at equally low levels in both cell lines. 
Interestingly, we could not detect any mRNA or protein 
expression of ELOVL2 in neither cell line. Downregulation 
of 17β-HSD12 did not lead to changes in expression of the 
analyzed enzymes, with the exception of decreased FADS1 
mRNA and protein levels in both cell lines (Fig. 3b, c), 
which may further accentuate the 17β-HSD12-knockdown 
phenotype.
Rescue of the effect of 17β‑HSD12 silencing 
on cancer cell proliferation and migration
Next, to test whether a deficiency in production of different 
LCFAs upon 17β-HSD12 silencing could account for the 
differential knockdown phenotypes, we downregulated the 
enzyme in the two cell lines and supplemented the medium 
with BSA-conjugated AA, EPA, and DHA, the FAs with 
the most well-studied role in cancer cell growth. We found 
that supplementation of AA in MDA-MB-231 cells led to a 
significantly greater increase in cell number and number of 
proliferating BrdU-positive cells at 48 h after 17β-HSD12-
knockdown (Fig. 4a; Suppl. Figure 6a and 6b). Although a 
similar trend of AA was observed on the migration ability 
of MDA-MB-231 cells after 17β-HSD12 downregulation, 
the difference compared to BSA-treated cells did not reach 
statistical significance. EPA and DHA supplementation did 
not affect the 17β-HSD12-knockdown proliferation pheno-
type, and EPA supplementation did not alter cell migration. 
In contrast, a complete rescue of decreased cell number 
72 h after 17β-HSD12 knockdown, and a decreased number 
of actively proliferating cells 48 h following 17β-HSD12 
downregulation, was observed upon EPA supplementation in 
SUM159 cells (Fig. 4b; Suppl. Figure 6a and 6b). Although 
AA treatment slightly reverted the number of proliferating 
cells 48 h after 17β-HSD12 knockdown (Suppl. Figure 6b), 
it failed to rescue the reduced cell number observed 72 h 
following 17β-HSD12 silencing (Fig. 4b; Suppl. Figure 6a). 
Importantly, EPA was equally able to rescue the reduc-
tion in cell migration following 17β-HSD12 silencing in 
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SUM159 cells (Fig. 4b). The above results imply that in 
MDA-MB-231 cells, AA under normal conditions sus-
tains cancer cell growth, possibly through downstream 
metabolism towards known mediators of inflammation that 
promote cell survival.
One of the most extensively investigated AA metabolites 
is prostaglandin E2 (PGE2), which is produced through 
Fig. 3  Possible determinants of the differential changes after 17β-
HSD12 downregulation in SUM159 and MDA-MB-231 cells. a (Left 
panel) SUM159 cells were cultured in Ham’s F12 nutrient mixture 
with insulin, or RPMI 1640 with or without insulin. 17β-HSD12 
expression was downregulated with siRNAs and cell number was 
determined 72 h later. (Right panel) Trans-well migration assay after 
17β-HSD12 silencing in SUM159 cells grown in Ham’s F12 nutri-
ent mixture with insulin or RPMI 1640 without insulin. The statis-
tical analyses compare mock- and 17β-HSD12-siRNA samples in 
each case (solid lines), as well as the difference between the mock-
17β-HSD12-siRNA groups under different culture conditions (dotted 
lines) (mean ± SD, n = 3, *p < 0.05, **p < 0.01, ns not significant). 
b (left panel) mRNA expression relative to PPIA of the indicated 
genes in MDA-MB-231 and SUM159 cells. (Middle and right pan-
els) mRNA expression of elongase (ELOVL5 and ELOVL7) and 
desaturase (FADS1 and FADS2) genes 48 h after 17β-HSD12 down-
regulation in MDA-MB-231 and SUM159 cells (mean ± SD, n = 4, 
*p < 0.05, **p < 0.01, ns not significant). c The expression of FADS1, 
FADS2 and ELOVL5 was analyzed by western blot 48 h after 17β-
HSD12 downregulation in MDA-MB-231 and SUM159 cells. A rep-
resentative blot (left panel) and analysis of band density from at least 
three independent experiments (right panel) is shown. Values are nor-
malized to mock siRNA samples (mean ± SD, *p < 0.05, **p < 0.01, 
ns not significant)
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the enzymatic function of cyclooxygenase 2 (Cox2). It is 
possible that in MDA-MB-231 cells, 17β-HSD12 antago-
nizes this pathway of AA metabolism by further elongat-
ing it towards longer FAs that do not support growth and 
migration. Interestingly, we found that the PGE2 cell surface 
receptor 2 (PTGER2) is expressed in MDA-MB-231 but not 
SUM159 cells and its levels are significantly upregulated 
after 17β-HSD12 downregulation (Fig. 4c). We could not 
detect mRNA expression of other PGE2 receptors (PTGER1, 
PTGER3, and PTGER4) in MDA-MB-231 or SUM159 
cells. Subsequently, we examined whether the Cox2 pathway 
of AA metabolism could be responsible for the increased 
proliferation upon 17β-HSD12 silencing in MDA-MB-231 
cells by treating mock- or 17β-HSD12 siRNA-transfected 
cells with the selective inhibitor Celecoxib (CEL). CEL 
treatment reverted the increased proliferation due to 17β-
HSD12 downregulation in MDA-MB-231 cells (Fig. 4c; 
Suppl. Figure 6c). In contrast, CEL treatment had no effect 
on the decreased proliferation of SUM159 cells after 17β-
HSD12 knockdown, supporting that this pathway does not 
Fig. 4  Fatty acids involved in the 17β-HSD12-knockdown pheno-
type. In MDA-MB-231 (a) and SUM159 (b) cells, cell number was 
determined after 17β-HSD12 knockdown and supplementation with 
BSA or BSA-conjugated DHA, EPA, and AA. The number of cells 
that migrated in a trans-well assay was counted after silencing of 
17β-HSD12 expression and treatment with BSA or BSA-conjugated 
EPA and AA. The statistical analysis shown compared the degree 
of difference between the various mock and 17β-HSD12 siRNA 
groups (mean ± SD, n = 4, *p < 0.05, **p < 0.01, ns not significant). 
c PTGER2 mRNA expression was measured in MDA-MB-231 cells 
48 h after 17β-HSD12 downregulation (mean ± SD, n = 4, *p < 0.05). 
No expression of PTGER2 could be detected in SUM159 cells. The 
number of MDA-MB-231 and SUM159 cells was assessed in mock- 
or 17β-HSD12-siRNA-transfected cells after treatment with DMSO 
or 1  μΜ of the Cox-2 inhibitor celecoxib (CEL) (mean ± SD, n = 3, 
*p < 0.05, **p < 0.01, ***p < 0.001, ns not significant). d The num-
ber of migrated cells was evaluated for MDA-MB-231 cells fol-
lowing 17β-HSD12 silencing and treatment with DMSO or CEL 
(mean ± SD, n = 3, *p < 0.05, ns not significant). e mRNA levels of 
the indicated genes in MDA-MB-231 and SUM159 cells (mean ± SD, 
n = 4, ***p < 0.001, ns not significant). f Cell number and migrating 
cells for MDA-MB-231 cells following treatment with DMSO or the 
CYP1B1 inhibitor TMS and mock or 17β-HSD12 siRNA transfec-
tion (mean ± SD, n = 3, *p < 0.05, ns not significant). g (Left panel) 
amount of AA (ng/ml/mg of protein) in extracts from mock- or 
17β-HSD12-siRNA-transfected MDA-MB-231 (n = 3) and SUM159 
cells (n = 4), as measured with a competitive ELISA assay. (Right 
panel) AA levels normalized to mock siRNA samples (mean ± SD, 
*p < 0.05, ns not significant)
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mediate the effect of 17β-HSD12 downregulation in this cell 
line (Fig. 4c; Suppl. Figure 6c). Furthermore, CEL was able 
to inhibit the increased migration triggered by 17β-HSD12 
knockdown in the MDA-MB-231 cells (Fig. 4d).
We then explored whether other pathways of AA metab-
olism are involved in the increased proliferation after 
17β-HSD12 silencing in MDA-MB-231 cells by analyz-
ing mRNA expression of the responsible enzymes. First, 
we tested the lipoxygenase enzymes (LOX5, LOX12, and 
LOX15) through which leukotrienes are produced. We did 
not find mRNA expression of any LOX enzyme in MDA-
MB-231 or SUM159 cells, with the exception of LOX5 
that was expressed at low levels in both. We then tested 
for expression of CYP450 enzymes, which convert AA to a 
plethora of biologically active metabolites, including epox-
yeicosatetraenoic acids (EETs) and hydroxyeicosatetraenoic 
acids (HETEs). Among the CYP450 enzymes analyzed 
(CYP1A2, CYP2J2, CYP4V2, CYP1B1, and CYP4F22), 
we detected measurable mRNA levels of CYP4V2 and 
CYP1B1. CYP4V2 was expressed at comparable levels in 
the two cell lines, but CYP1B1 mRNA was substantially 
expressed only in MDA-MB-231 cells, suggesting a possible 
role of this enzyme in the observed effects (Fig. 4e). To test 
whether CYP1B1 could mediate the increase in proliferation 
and migration induced after 17β-HSD12 downregulation in 
MDA-MB-231 cells, we used the CYP1B1 inhibitor TMS. 
TMS treatment abolished the 17β-HSD12 downregulation-
dependent increase in proliferation and migration of MDA-
MB-231 cells (Fig. 4f). AA incorporated into membrane 
phospholipids has been shown to promote proliferation 
through the Akt survival pathway. Unexpectedly, knock-
down of 17β-HSD12 in MDA-MB-231 cells decreased the 
ratio of activated Akt phosphorylated on Ser473 to total 
Akt levels (Suppl. Figure 6d). Intriguingly, measurement 
of AA levels with a competitive ELISA assay showed that 
the levels of cellular AA are lower in SUM159 compared 
to MDA-MB-231 cells (Fig. 4g). Furthermore, 17β-HSD12 
knockdown did not alter AA levels in SUM159, while it 
decreased its levels in MDA-MB-231 cells. This could be 
due to upregulation of AA processing by COX and CYP 
enzymes to downstream metabolites, which supports the 
results of the previously described findings (Fig. 4c, d, f).
Impact of 17β‑HSD12 silencing on energy 
metabolism
We subsequently examined whether inhibition of the biosyn-
thetic pathway for LCFAs can trigger metabolic rewiring in 
cancer cells. This could be a direct consequence of utiliza-
tion of these FAs as energy sources or indirect through the 
pleiotropic effects of LCFAs on cancer cell physiology. We 
first measured in real-time OCR, indicative of one of the 
main pathways for energy production in cells, mitochondrial 
oxidative phosphorylation (OXPHOS). For comparison 
and potential correlation with the proliferation phenotypes 
observed after 17β-HSD12 silencing, we used in these 
experiments MDA-MB-231 and SUM159 cells both grown 
in RPMI 1640 medium. We first measured mitochondrial 
respiration using the Seahorse Mitostress test (see materi-
als and methods), where a sequential addition of stressors 
(oligomycin, FCCP, and antimycin/rotenone) allows cal-
culating the different parameters of mitochondrial respira-
tion (basal respiration, ATP production, maximal respira-
tion, spare capacity, and proton leak), as well as the part of 
OCR attributed to non-mitochondrial oxygen consumption. 
LCFAs are first oxidized in peroxisomes, and after reach-
ing a certain length can be transferred to mitochondria for 
further breakdown [30]. To assess the potential contribution 
of FA oxidation in the measured OCR, we used Etomoxir 
(Eto), an irreversible inhibitor of carnitine palmitoyltrans-
ferase 1 that blocks mitochondrial β-oxidation, and the spe-
cific inhibitor of peroxisomal β-oxidation Thio [31, 32]. The 
experiments were performed 48 h post-transfection, a time 
point when the difference in proliferation between mock- and 
17β-HSD12-siRNA-transfected cells is not yet evident in 
SUM159 cells. Our results showed that the baseline OCR, 
ATP production, maximal respiration, and spare respira-
tory capacity were significantly reduced after 17β-HSD12 
silencing in SUM159 but not in MDA-MB-231 cells (Fig. 5; 
Suppl. Figure 7a). Proton leak and non-mitochondrial res-
piration were not affected in neither cell line. Eto treatment 
significantly reduced basal respiration, mitochondrial ATP 
production, and maximal respiration in both cell lines, dem-
onstrating that β-oxidation is an overriding factor for these 
cancer cells. Treatment with Thio reduced ATP production 
in SUM159 but not MDA-MB-231 cells. However, a dra-
matic decline in maximal respiration and spare respiratory 
capacity is observed in both cell lines after Thio treatment. 
Interestingly, Thio but not Eto treatment leads to a signifi-
cant rise in proton leak in both cell lines.
Since Eto and Thio treatment reduced ATP production as 
well as spare respiratory capacity in MDA-MB-231 cells, 
we reasoned that β-oxidation could be vital in sustaining 
proliferation after 17β-HSD12 silencing in this cell line. 
Following downregulation of 17β-HSD12 expression and 
treatment of MDA-MB-231 cells with or without 1 μΜ Eto 
or Thio for 24 h, the 17β-HSD12 downregulation-dependent 
increased cell proliferation was suppressed after inhibition 
of mitochondrial or peroxisomal β-oxidation (Fig. 6a; Suppl. 
Figure 7b).
To further explore possible sources of energy and/or 
building blocks permitting increased proliferation and 
migratory potential of MDA-MB-231 cells after 17β-HSD12 
silencing, we investigated whether glutamine metabolism, 
a major pathway in supporting cancer cell growth, was 
involved [33]. Our results showed that glutamine depletion 
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for 48 h did not alter the 17β-HSD12 knockdown-dependent 
increase in proliferation and migration (Suppl. Figure 8a).
Another fundamental cellular energy source is glucose. 
Through glycolysis, glucose can be converted to pyruvate 
and then lactate, resulting in extrusion of protons into the 
extracellular medium. Pyruvate produced through glyco-
lysis can also enter the TCA cycle in mitochondria, which 
produces NADH and FADH2 that are utilized in OXPHOS 
Fig. 5  Influence of 17β-HSD12 silencing on oxygen consumption. 
OCR was measured in real time using the Seahorse XF96 analyzer, 
48  h after 17β-HSD12 downregulation in SUM159 and MDA-
MB-231 cells. Different parameters of mitochondrial function (basal 
respiration, ATP production, maximal respiration, spare respira-
tory capacity, and proton leak), as well as non-mitochondrial oxygen 
consumption were calculated employing the Seahorse XF Cell Mito 
Stress Test. Samples were left untreated (ctrl) or treated with the 
β-oxidation inhibitors Eto (mitochondrial) or Thio (peroxisomal). The 
statistical analysis depicted in blue characters compared the differ-
ences in the values between the corresponding mock siRNA and 17β-
HSD12 siRNA samples. The rest of the statistical analysis shown in 
black letters was performed to study the differences between the indi-
cated groups (mean ± SD, n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, 
ns not significant)
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Fig. 6  Effect of β-oxidation and glucose metabolism on the phe-
notype of 17β-HSD12 silencing. a Number of MDA-MB-231 cells 
counted 48  h post mock- or 17β-HSD12-siRNA transfection and 
24  h after treatment with the inhibitor of mitochondrial β-oxidation 
Eto (top, n = 6) or peroxisomal β-oxidation Thio (bottom, n = 5) 
(mean ± SD, *p < 0.05, ns not significant). b ECAR was measured 
for MDA-MB-231 and SUM159 cells at baseline using the Sea-
horse XF96 analyzer during the experiments described in Fig.  5 
(mean ± SD, n = 5, **p < 0.01, ns not significant). The statistical anal-
ysis depicted in blue characters compared the differences in the val-
ues between the corresponding mock siRNA and 17β-HSD12 siRNA 
samples. c Cells counted after knockdown of 17β-HSD12 in MDA-
MB-231 (n = 4) and SUM159 (n = 5) cells and culturing in RPMI 
1640 medium-containing 4  g/l, 2  g/l or 0.5  g/l glucose. The dotted 
lines represent the statistical comparison between the different mock 
siRNA/17β-HSD12 siRNA groups, whereas the solid lines consti-
tute comparison between the indicated mock siRNA and 17β-HSD12 
siRNA samples (mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.01, 
ns not significant). d The levels of G6PD in MDA-MB-231 and 
SUM159 cells were assessed by western blot and quantified by densi-
tometry (mean ± SD, n = 4, *p < 0.05, ns not significant)
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to generate more ATP. Alternatively, glucose can enter the 
pentose phosphate pathway (PPP) that produces NADPH as 
well as important building blocks, such as ribonucleotides. 
The first rate-limiting enzyme in this metabolic pathway is 
glucose 6-phosphate dehydrogenase (G6PD), which converts 
glucose 6-phosphate to 6-phosphogluconate, thereby gener-
ating NADPH. To gain more insight into the role of glucose 
after 17β-HSD12 knockdown, we first measured in real-time 
ECAR as a measure of glycolysis. Our results showed no sig-
nificant difference in the levels of ECAR after 17β-HSD12 
silencing in MDA-MB-231 or SUM159 cells (Fig. 6b). Inhi-
bition of β-oxidation with Eto led to a compensatory increase 
in glycolysis in both cell lines, whereas Thio had no effect. 
However, Thio caused significant decrease in glycolysis after 
17β-HSD12 knockdown only in SUM159 cells. To conclude 
whether glucose could play another role in growth of these 
cell lines following 17β-HSD12 silencing, we cultured 
SUM159 and MDA-MB-231 cells in RPMI 1640 medium-
containing normal (2 g/l), higher (4 g/l), or lower (0.5 g/l) 
glucose concentration (Fig. 6c). Surprisingly, increasing the 
amount of glucose in MDA-MB-231 cells dampened the 
17β-HSD12-knockdown phenotype, and decreasing glucose 
concentration led to a further accentuation of the phenotype. 
This was opposite to what we observed in SUM159 cells, 
where increased glucose rescued the reduction in prolifera-
tion following 17β-HSD12 silencing (Fig. 6c). No change 
in the 17β-HSD12-knockdown phenotype was observed at 
lower glucose concentrations. Interestingly, G6PD expres-
sion was found to be significantly increased in SUM159 after 
knockdown of 17β-HSD12, while it was unaltered in MDA-
MB-231 cells (Fig. 6d). No difference in the expression of 
the second NADPH-producing enzyme of the PPP, phos-
phogluconate dehydrogenase (PGD) was observed in neither 
cell line after 17β-HSD12 knockdown (Suppl. Figure 8b). 
Taken together, the above results point towards a significant 
difference in glucose utilization between the two cell lines.
Alteration in ER stress response and folding 
pathways after 17β‑HSD12 knockdown
Long-chain fatty acids elongation takes place at the ER, the 
compartment where the cellular machineries for protein fold-
ing and stress response pathways reside. Nutrient depletion 
or defects in biosynthetic pathways induce a multitude of 
stress signals, although this has not been investigated for 
LCFAs. To address this, we first assessed the effects of 17β-
HSD12 silencing on the UPR pathway. The UPR is activated 
through diverse stressors, including overload of protein 
folding demand in the ER, oxidative stress, and shortage in 
energy sources. It is well recognized that cancer cells exploit 
the UPR to sustain their high proliferation rates, resulting 
in constitutive overactivation of several UPR components 
[34]. The UPR consists of three main branches [35]; the 
protein kinase R-like ER kinase/eukaryotic initiation factor 
2α (PERK/eIF2α), the inositol-requiring enzyme 1α/split 
X-box-binding protein 1 (IRE1α-Xbp1), and the activating 
transcription factor 6 (ATF6).
First, we downregulated 17β-HSD12 and performed 
western blot analysis for several UPR components at 48 h 
after knockdown in SUM159 and MDA-MB-231 cells. The 
first UPR branch is initiated by phosphorylation of PERK 
or other kinases, which in turn phosphorylate/activate eIF2α 
that selectively increases translation of specific mRNAs, 
including that of activating transcription factor 4 (ATF4). 
Activated ATF4 promotes transcription of target genes, 
and most commonly that of CCAAT/enhancer-binding 
protein homologous protein (CHOP, also known as DNA 
damage-inducible transcript 3 protein DDIT3). Following 
17β-HSD12 downregulation in both SUM159 and MDA-
MB-231 cells, we found increased phosphorylation of eIF2α 
(peIF2α), whereas total eIF2α protein levels remained stable 
(Fig. 7a). The total levels of PERK after 17β-HSD12 down-
regulation were unaffected (Suppl. Figure 9a); however, 
due to the lack of a specific antibody against pPERK, we 
could not conclude whether the increased phosphorylation 
of eIF2α was triggered by PERK or another kinase. The fact 
that eIF2α was activated irrespective of the differential effect 
on proliferation of 17β-HSD12 silencing in the two cell lines 
implies that this is a common cellular response upon defec-
tive LCFA biosynthesis. Notably, eIF2α downregulation 
led to a dramatic reduction of 17β-HSD12 mRNA levels 
(Fig. 7b). Knockdown of eIF2α in SUM159 cells caused a 
significant reduction in cell number and number of prolifer-
ating cells, mimicking 17β-HSD12 silencing (Fig. 7c; Suppl. 
Figure 9b). No effect on proliferation was observed after 
eIF2α knockdown in MDA-MB-231 cells, which could mean 
that the reduction in 17β-HSD12 levels after eIF2α down-
regulation is not sufficient to recapitulate the 17β-HSD12-
knockdown phenotype in this cell line.
Although ATF4 is a target of eIF2a, 17β-HSD12 siRNA 
transfection led to decreased ATF4 protein levels in SUM159 
cells, while it had no effect in MDA-MB-231 cells (Fig. 7d). 
This demonstrates that although eIF2α is activated upon 
17β-HSD12 silencing, it does not stabilize ATF4 protein as 
expected, which further suggests that it constitutes a coun-
terbalance mechanism. In addition, in SUM159 cells ATF4 
ran in western blot as a triplet, likely representing different 
degrees of phosphorylation, whereas only one band could 
be detected in the MDA-MB-231 cells (Fig. 7d), indicat-
ing different degrees of ATF4 activation between the two 
cell lines. Furthermore, the mRNA and protein levels of the 
ATF4 target CHOP significantly declined in both cell lines 
following 17β-HSD12 silencing (Fig. 8a; Suppl. Figure 9c 
and d). The levels of the downstream CHOP target GADD34 
(growth arrest and DNA damage-inducible protein 34), the 
phosphatase that dephosphorylates eIF2α, were reduced, 
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which can explain the increased eIF2α phosphorylation 
(Fig. 8a). Since no difference in ATF4 following 17β-HSD12 
downregulation was found in MDA-MB-231 cells, CHOP 
expression is possibly regulated by transcription factors 
other than ATF4, at least in this cell line. CHOP has been 
shown to be a retinoid-responsive gene [36]. Therefore, 
we investigated whether its expression is regulated by reti-
noid X receptor alpha (RXRα), since this receptor has been 
Fig. 7  Alterations in the eIF2α/ATF4 pathway upon 17β-HSD12 
downregulation. a Western blot analysis for protein expression of 
eIF2α and peIF2a after 17β-HSD12 knockdown in MDA-MB-231 
(n = 6) and SUM159 (n = 3) cells. A representative blot and densi-
tometry analysis of all independent experiments are shown. From 
the individual densities of eIF2α and peIF2, the rate of eIF2α phos-
phorylation was calculated (mean ± SD, *p < 0.05, **p < 0.01). b 
MDA-MB-231 and SUM159 cells were transfected with mock-, 
eIF2α-, 17β-HSD12- or eIF2α and 17β-HSD12-siRNA and the lev-
els of 17β-HSD12 mRNA were measured by qPCR (mean ± SD, 
n = 4, *p < 0.05, ***p < 0.001). c MDA-MB-231 (n = 7) and SUM159 
(n = 4) cells were treated as in Fig.  7b and cell number was evalu-
ated in the different samples (mean ± SD, *p < 0.05, **p < 0.01, 
***p < 0.001, ns not significant). d The expression of ATF4 protein 
was evaluated by western blot in MDA-MB-231 and SUM159 cells 
48 h after 17β-HSD12 downregulation (mean ± SD, n = 4, *p < 0.05, 
ns not significant)
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linked with cell proliferation control, and we found it to be 
abundantly expressed in both SUM159 and MDA-MB-231 
cells. To examine whether the reduced CHOP levels fol-
lowing 17-HSD12 downregulation could be mediated by 
reduced expression of RXRα, we determined RXRα lev-
els. In accordance with our hypothesis, RXRα levels were 
reduced at the mRNA and protein level in both cell lines 
after 17β-HSD12 silencing (Fig. 8b; Suppl. Figure 9d). 
Moreover, downregulation of RXRα led to decreased CHOP 
mRNA levels, comparable to that observed after 17β-HSD12 
silencing, while it had no impact on 17β-HSD12 mRNA 
expression (Fig. 8c). Regarding the other UPR pathways, 
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we found no difference in the levels of ATF6 or sXBP1 (the 
active form of XBP1 that initiates IRE1α-mediated signals) 
in neither cell line 48 h following 17β-HSD12 knockdown 
(Suppl. Figure 9e and f). Consequently, these UPR branches 
were not pursued further.
Since the UPR pathway is closely related to protein fold-
ing, we also examined a potential influence of 17β-HSD12 
downregulation on several protein folding components. 
Among the proteins involved in folding are the heat-shock 
responsive proteins, including Grp78 and Grp94, which 
were not affected by silencing of 17β-HSD12 (Suppl. Fig-
ure 10a). One of the most important families of folding-
control proteins is the protein disulfide isomerases (PDI). 
Although the expression of two members of this family, 
namely PDI and ERp72, was not changed following 17β-
HSD12 downregulation (Suppl. Figure 10b), there was a 
significant increase in ERp44 expression at the mRNA and 
protein levels in both SUM159 and MDA-MB-231 cells 
(Fig. 8d; Suppl. Figure 10c). Given that eIF2α was overac-
tivated after 17β-HSD12 knockdown, we examined whether 
it could be involved in stabilizing the ERp44 mRNA. In con-
trast to this hypothesis, knockdown of eIF2α led to a small 
rise in the levels of ERp44 (Suppl. Figure 10d).
Discussion
The rapid growth of cancer cells requires a high amount of 
energy and macromolecules, including carbohydrates, pro-
teins, lipids, and nucleic acids. These demands are largely 
met by metabolic rewiring, which entails de novo synthesis 
of cellular building blocks. The role of FAs in malignant 
transformation is highly relevant, with a multitude of altera-
tions in FA synthesis and break down through β-oxidation 
reported in several types of cancer [37]. Besides, certain 
FAs act as signaling molecules and are involved in meta-
bolic adaptation. This work addressed the role of LCFA 
biosynthesis for cancer cells. Of the four enzymatic entities 
participating in LCFA synthesis, 17β-HSD12 has garnered 
attention regarding its role in cancer through studies yielding 
conflicting results. While some studies reported an associa-
tion of 17β-HSD12 with more aggressive tumor progres-
sion and poor outcome [21–23], others found a suppressive 
role [25]. Using different breast cancer cells, we showed 
that silencing of 17β-HSD12 either increases or decreases 
cancer cell proliferation and migration depending on the cel-
lular context. Importantly, two triple-negative breast can-
cer cell lines, MDA-MB-231 and SUM159, exhibit oppo-
site phenotypes with increased and decreased proliferation 
and migration, respectively, after 17β-HSD12 knockdown, 
emphasizing the heterogeneity of breast cancer cells (results 
summarized in Fig. 8e). In a previous report, 17β-HSD12 
downregulation caused a dramatic decrease in proliferation 
after culturing the cells in serum-free medium during knock-
down, a condition that severely hinders cell growth [21]. Our 
experiments were performed under normal culture condi-
tions, highlighting that even under sufficient energy supply, 
impaired LCFA synthesis affects cancer cell proliferation 
and invasiveness. The effect of 17β-HSD12 knockdown 
on cell migration was followed by changes in the levels of 
MMPs that were not accompanied by altered cell adhesion. 
This suggests that they likely represent offset mechanisms to 
initial alterations in the molecular network controlling cell 
substrate attachment after 17β-HSD12 silencing.
To understand the differential impact of 17β-HSD12 
downregulation, we compared MDA-MB-231 and SUM159 
cells. Differences in the culture medium could not explain 
the observed divergent phenotypes of the two cell lines fol-
lowing 17β-HSD12 silencing; therefore, we explored the 
expression of enzymes participating in LCFA synthesis, 
focusing on ω-6 and ω-3 PUFAs. Since HACDs 1–4 show 
tissue but not substrate specificities, and only one TER and 
one KAR enzyme have been identified so far [38, 39], we 
tested whether distinct expression of ELOVLs with different 
substrate specificities directs differential FA synthesis in the 
two cell lines. Expression of ELOVL2, which is indispensa-
ble for the elongation of PUFAs with 22 carbon atoms [40, 
41] (Fig. 1b), was not detected in the two cell lines, suggest-
ing that this process does not take place in these cells and 
resembling the situation in proliferating T cells [42]. In addi-
tion, we found that ELOVL5 mRNA and protein expression 
was lower in SUM159 compared to MDA-MB-231 cells. 
ELOVL5 elongates 18 carbon PUFAs as well as PUFAs with 
Fig. 8  Effect of 17β-HSD12 knockdown on CHOP and ERp44 
expression. a The protein levels of CHOP were assessed by west-
ern blot 48  h after 17β-HSD12 silencing in SUM159 cells. mRNA 
expression of the CHOP target GADD34 in MDA-MB-231 
and SUM159 cells 48  h following 17β-HSD12 downregulation 
(mean ± SD, n = 4, *p < 0.05, **p < 0.01). b Expression of RXRα 
protein 48  h after 17β-HSD12 knockdown in MDA-MB-231 and 
SUM159 cells (mean ± SD, n = 4, *p < 0.05). c SUM159 cells 
were transfected with mock-, RXRα-, 17β-HSD12- or RXRα- and 
17β-HSD12-siRNA, and CHOP or 17β-HSD12 mRNA expression 
was assessed by qPCR (mean ± SD, n = 5, *p < 0.05, **p < 0.01, 
***p < 0.001, ns not significant). d The levels of the folding pro-
tein ERp44 were analyzed by western blot following 17β-HSD12 
knockdown in MDA-MB-231 and SUM159 cells (mean ± SD, n = 5, 
**p < 0.01, ***p < 0.001). e Summary of the most prominent cel-
lular changes observed in MDA-MB-231 and SUM159 cells after 
17β-HSD12 knockdown. (Left panel) In SUM159 cells, 17β-HSD12 
downregulation leads to decreased proliferation and migration, which 
can be restored by EPA supplementation. Aberration in synthesis 
of other FAs could additionally lead to the observed phenotype. In 
MDA-MB-231 cells, knockdown of 17β-HSD12 leads to increased 
AA metabolism through the COX and CYPB1 pathways that promote 
proliferation and migration. The augmented proliferation after 17β-
HSD12 knockdown is supported by energy and/or building blocks 
provided by β-oxidation. (Right panel) Comparison of the altera-
tions in UPR/folding and energy metabolism in SUM159 and MDA-
MB-231 cells following 17β-HSD12 silencing
◂
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20 carbon atoms such as AA and EPA, and several stud-
ies indicated a preference of this enzyme for ω-3 FAs [40, 
42–45]. This could mean that at the low ELOVL5 expression 
in SUM159 cells, the activity is directed towards EPA over 
AA elongation. The FADS enzymes also display substrate 
specificities in PUFA elongation (Fig. 1b). Although we 
found much lower FADS2 mRNA levels in SUM159 than 
in MDA-MB-231 cells, western blot revealed similar pro-
tein expression in both cell lines. This discrepancy between 
mRNA and protein levels could be due to a higher rate of 
FADS2 mRNA translation in SUM159 compared with 
MDA-MB-231 cells, resulting in comparable protein levels. 
Nevertheless, because protein expression is not significantly 
different between the two cells, FADS2 unlikely is respon-
sible for the observed differences in their proliferation after 
17β-HSD12 knockdown. Future experiments should include 
a complete proteomics profiling in the two cancer cell lines 
to unveil key differences in other enzymes participating in 
synthesis of saturated and monounsaturated LCFAs.
According to one of our hypotheses, the production 
of different LCFAs in MDA-MB-231 and SUM159 cells 
could account for the different phenotypes after 17β-HSD12 
knockdown. Indeed, supplementation with EPA following 
17β-HSD12 silencing rescued the decreased proliferation 
and migration of SUM159 cells. It is unclear whether this is 
a direct effect or caused through formation of downstream 
metabolites. AA or DHA supplementation failed to revert 
the 17β-HSD12-knockdown phenotype, supporting an EPA-
specific effect. This finding was unexpected, since EPA was 
associated with suppression of breast cancer cell growth 
[46]. However, EPA treatment was shown to increase pro-
liferation of RAW264.7 macrophages and of a B-lymphocyte 
cell line, which in the latter was attributed to the absence of 
EPA-to-DHA conversion [47, 48]. Due to swift conversion 
of EPA to DHA in certain cell types, the effects of the two 
FAs cannot always be distinguished. In MDA-MB-231 cells, 
AA exacerbated the 17β-HSD12 siRNA-induced rise in cell 
proliferation, whereas EPA and DHA had no impact. We 
reasoned that this might be due to AA conversion towards 
eicosanoids promoting cancer cell growth and invasiveness. 
Indeed, blocking the activities of COX2 and CYP1B1 that 
are involved in this metabolism reverted the effect of 17β-
HSD12 knockdown on MDA-MB-231 cells, indicating that 
in this cell line, elongation of AA competes with its pro-
cessing through eicosanoid synthesis pathways. Of note, 
CYP1B1 is not expressed in SUM159 cells, and inhibiting 
COX2 did not alter the proliferation phenotype after 17β-
HSD12 silencing. Importantly, 17β-HSD12 silencing led to 
a change in AA levels exclusively in MDA-MB-231 cells. 
Downstream metabolism of AA through COX and CYP 
enzymes may, consequently, promote cancer cell growth 
and migratory potential. Taken together, our results suggest 
that the metabolism of AA and EPA is implicated in the 
observed phenotypes after 17β-HSD12 silencing in MDA-
MB-231 and SUM159 cells, respectively. In addition, differ-
ential AA metabolism emerges as a crucial divergent point 
between the two cell lines, which offers an explanation for 
the differential 17β-HSD12-knockdown phenotype. After 
AA release from membrane phospholipids by phospholipase 
A2, cell proliferation was found to be induced via activa-
tion of the serine–threonine kinase Akt [49–51]. Surpris-
ingly, our results showed reduced phosphorylation of Akt 
at Ser473 at 48 h after 17β-HSD12 downregulation. This 
finding may be explained by a negative feedback loop after 
a transient increase in Akt phosphorylation or alternative 
survival pathways in this cell system.
Since our analysis covered only a small fraction of the 
possible FAs affected by 17β-HSD12 downregulation, future 
lipidomics analysis should provide a comprehensive picture 
of the changes following defects in LCFA synthesis in dif-
ferent cancer cell lines. Reliable methods for detailed and 
time-effective analysis of lipidomes in cells and various 
organisms have lately been developed [52]. Our preliminary 
experiments in SUM159 cells indicate a shift from longer 
to shorter chain LCFAs upon 17β-HSD12 knockdown (data 
not shown).
Since FAs are hardly soluble in aqueous solutions, for our 
experiments, FAs were conjugated with BSA, as previously 
described [53, 54]. Before entering cells, FAs dissociate 
from BSA and are intracellularly transported in a free form 
either through diffusion or protein-mediated transport [55]. 
In addition, free FAs can bind to G protein-coupled receptors 
at the cell surface, thereby exerting signaling effects that can 
affect tumor growth and chemoresistance [56, 57]. The most 
important receptors mediating LCFA action are GPR40 and 
GPR120, whereby GPR40 was shown to potentiate some 
of the effects of free FAs in MDA-MB-231 cells [58, 59]. 
Thus, it would be interesting to explore whether the pheno-
types observed after 17β-HSD12 knockdown and treatment 
of cells with FAs are influenced by these receptors.
By altering the metabolic phenotype of cancer cells, 
impaired LCFA synthesis could mediate effects on cell pro-
liferation upon 17β-HSD12 silencing. Our results revealed 
that 17β-HSD12 knockdown decreased ATP produc-
tion through OXPHOS in SUM159 cells, whereas MDA-
MB-231 cells appeared resistant. It should be noted that 
these experiments were performed 48 h after 17β-HSD12 
siRNA transfection, a time point when SUM159 cell prolif-
eration was not yet significantly reduced, implying that the 
decreased OXPHOS precedes impairments of proliferation 
and suggesting a causative effect. Inhibition of peroxisomal 
β-oxidation with Thio markedly decreased maximal respira-
tion and spare respiratory capacity, which may have crucial 
consequences when cells grow under conditions requiring 
mobilization of their energy reserves. Strikingly, blockage 
of peroxisomal β-oxidation led to an increased proton leak. 
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Proton leak is considered a protective mechanism against 
reactive oxygen species (ROS) generation and, in turn, ROS 
are known to promote proton leak [60]. The observed rise 
in proton leak could be a consequence of increased ROS 
after Thio treatment or a reaction to increased ROS forma-
tion. Blocking peroxisomal β-oxidation could augment the 
amount of free LCFAs, which have been shown to carry 
protons across the mitochondrial membrane, by shuffling 
between the protonated and non-protonated states [61, 
62]. Inhibiting mitochondrial β-oxidation severely blocks 
OXPHOS in both cell lines, indicating that breakdown of 
FAs is a major contributor to mitochondrial ATP produc-
tion. This is mainly mediated by acetyl-CoA production, 
the ultimate product of β-oxidation, which can readily enter 
the TCA cycle that subsequently fuels the electron trans-
port chain [63]. Since we found β-oxidation to be a prevail-
ing factor in sustaining ATP production through OXPHOS, 
we examined whether it mediates the increased prolifera-
tion observed after 17β-HSD12 downregulation in MDA-
MB-231 cells. In line with our hypothesis, inhibition of 
mitochondrial or peroxisomal β-oxidation attenuated the 
17β-HSD12-knockdown effect on the proliferation of these 
cells. Although peroxisomal β-oxidation does not directly 
yield ATP, further breakdown of FAs in mitochondria links 
the two β-oxidation pathways.
A key metabolite supporting cancer cell growth is glu-
cose. Based on live measurements of ECAR, we concluded 
that 17β-HSD12 downregulation does not affect glycolysis 
in neither cell line. However, the expression of G6PD, the 
enzyme catalyzing the first and rate-limiting enzyme in the 
PPP of glucose metabolism, was upregulated upon silencing 
of 17β-HSD12 only in SUM159 cells. Through the enzy-
matic conversion of glucose 6-phosphate, G6PD generates 
NADPH, an essential co-factor for the synthesis of short-
chain FAs by FAS in the cytosol. The importance of the 
PPP for tumor cells has recently started to be recognized 
[64]. Silencing of G6PD MCF7 breast cancer cells reduced 
lipid synthesis and proliferation [65]. Importantly, in the 
present study, increased glucose concentration in the cul-
ture medium fully restored proliferation after 17β-HSD12 
knockdown in SUM159 cells. In contrast, increased glucose 
concentration suppressed the increased proliferation upon 
17β-HSD12 downregulation in MDA-MB-231 cells, while 
decreased glucose concentration further enhanced prolif-
eration. These results imply that the cellular pathways in 
which glucose participates are competitive to the ones that 
MDA-MB-231 cells utilize to boost proliferation after 17β-
HSD12 knockdown. This may be explained by competition 
between glycolysis and the β-oxidation pathway that sustains 
high proliferation after 17β-HSD12 silencing. Although both 
glycolysis and β-oxidation produce acetyl-CoA that fuels 
the TCA cycle, β-oxidation is more efficient by provid-
ing a higher number of carbon atoms per molecule [66]. 
β-oxidation of FAs can thus generate more ATP molecules 
than glycolysis. In accordance, we demonstrated that the 
majority of OXPHOS in both cancer cell lines is fueled by 
β-oxidation.
It has recently been recognized that the UPR pathway is 
of paramount importance for tumor cell growth, due to its 
role in maintaining excessive bioenergetic needs and growth 
under hypoxic and nutrient-limited conditions. Importantly, 
the UPR is constantly alert to changes in lipid metabolism. 
For example, membrane lipid composition directly triggers 
the UPR, irrespective of proteostasis, and perturbations 
in ER membrane lipid composition activate several UPR 
components, including PERK and IRE1 [67, 68]. Interest-
ingly, we found that 17β-HSD12 downregulation induced 
the phosphorylation/activation of eIF2α. Downregulation 
of eIF2α drastically decreased 17β-HSD12 levels, imply-
ing that 17β-HSD12 expression is controlled by eIF2α, and 
mimicked some of the effects observed after 17β-HSD12 
knockdown, such as the decreased proliferation of SUM159 
cells. The increased phosphorylation of eIF2α after 17β-
HSD12 knockdown could thus represent a compensatory 
mechanism. Upon activation, eIF2α induces a global reduc-
tion in protein synthesis, but specifically enhances transla-
tion of certain mRNAs through the control of translation 
from upstream open reading frames (sORF) [69]. The only 
mRNA that has been unequivocally shown to be subjected 
to such regulation is that of ATF4. Since ATF4 was reduced 
when eIF2α was activated in the SUM159 cells, and we did 
not observe any general attenuation of protein synthesis in 
neither cell line after 17β-HSD12 knockdown, we conclude 
that activation of eIF2a is a response to the decreased 17β-
HSD12 mRNA levels. In this context, it would be interesting 
to investigate whether 17β-HSD12 is an mRNA stabilized by 
eIF2α and whether other lipid metabolizing enzymes could 
be subject to this type of regulation.
Another UPR component modified by 17β-HSD12 
knockdown in SUM159 and MDA-MB-231 cells was 
CHOP, exhibiting a decrease at both mRNA and protein 
levels. CHOP is a transcription factor that can be activated 
by both the eIF2a/ATF4 and ATF6 branches of the UPR, and 
has been associated with ER stress-induced apoptosis [70]. 
However, CHOP is abundantly expressed in MDA-MB-231 
and SUM159 cells at steady state, pointing towards an 
alternative function of this factor in these cells. In addition, 
CHOP expression was reduced after 17β-HSD12 knock-
down in both cell lines, independently of the proliferation 
rate. Recent evidence suggests that CHOP possesses a dual 
function; it regulates apoptosis after extensive stressful 
stimuli, such as amino acid deprivation, but also induces 
the expression of autophagy-related genes at initial stages of 
starvation [71, 72]. Therefore, CHOP expression in tumor 
cells at basal levels may control autophagy, a cellular pro-
cess with a crucial role for survival of many tumors [73]. 
1172 M. Tsachaki et al.
1 3
Among others, autophagy encompasses lipid degradation to 
free FAs (lipophagy) that fuels β-oxidation [74]. It is thus 
possible that CHOP sustains growth of tumor cells through 
maintaining signals for optimal autophagy levels, includ-
ing lipid recycling. In addition, studies in  CHOP−/− mice 
have shown that it directly regulates the expression of mas-
ter regulators of lipid metabolism, such as sterol regulatory 
element-binding proteins (SREBPs) and the peroxisome pro-
liferator-activated receptor alpha (PPARα) [75]. This favors 
a role of CHOP in sustaining cancer cell growth through the 
control of metabolic genes. The mechanism of how CHOP 
expression was reduced after 17β-HSD12 downregulation 
remains to be discovered. In liver, FXR/RXR heterodimers 
regulate CHOP expression; therefore, we tested the poten-
tial involvement of RXRα, which is abundantly expressed 
in MDA-MB-231 and SUM159 cells. 17β-HSD12 knock-
down diminished RXRα mRNA and protein levels, and 
RXRα downregulation led to decreased CHOP levels, as 
also observed after 17β-HSD12 downregulation. Although 
a direct link cannot be drawn from these experiments, our 
results suggest RXRα as a candidate regulator of CHOP 
expression.
Examination of folding-control proteins revealed activa-
tion of ERp44 as a common denominator of 17β-HSD12 
silencing in MDA-MB-231 and SUM159 cells. This increase 
of ERp44 did not seem to be controlled by eIF2α; silencing 
eIF2α led to a small increase in ERp44 expression, which 
could be due to the decreased 17β-HSD12 levels upon 
eIF2α silencing. These data further support that eIF2α is 
upstream of 17β-HSD12 and controls its expression. ERp44 
is an interesting member of the PDI family, since it shunts 
between the ER, ER–Golgi intermediate compartment 
(ERGIC), and cis-Golgi [76, 77]. It is dormant in the ER 
but active in more distal compartments where it binds to its 
client proteins, releasing them only when their maturation 
is complete. Among the proteins falling into ERp44 quality 
control are multimeric proteins, such as immunoglobin M 
(IgM) and adiponectin [78–80]. Increased ERp44 expres-
sion may be a consequence of high demand in folding of 
specific proteins or triggered by other stimuli, such as redox 
status imbalance provoked by 17β-HSD12 silencing. ERp44 
knockdown induced apoptosis in HeLa cells, while ERp44 
expression inhibited migration in the human non-small lung 
cancer cell line A549 through a pathway involving inositol 
1,4,5-trisphosphate receptor type 2 (IP3R2) [81, 82]. Given 
that the ERp44 increase after 17β-HSD12 downregulation 
was followed by decreased and increased proliferation/
migration in SUM159 and MDA-MB-231 cells, respectively, 
it is likely that ERp44 upregulation is an early event follow-
ing impaired LCFA synthesis. Its specific involvement in 
tumor cell homeostasis warrants further investigation.
High 17β-HSD12 expression has been associated with 
poor prognosis in breast and ovarian cancer patients [21–23]. 
At the same time, 17β-HSD12 was found to be a prognostic 
marker gene for favorable and adverse outcome in patients 
with kidney and liver cancer, respectively [25]. Our study 
explains these apparently contradicting results, since we 
showed that the phenotype after 17β-HSD12 silencing could 
diverge, depending on the cellular context. The complex bio-
synthetic pathway of LCFA synthesis, the pleiotropic effects 
of the produced FAs, as well as the differential responses of 
different types of cells to impaired biochemical processes, 
could all underlie the divergent phenotype upon downregu-
lation of 17β-HSD12 expression. The notion that genes can 
be categorized as cancer promoting or suppressing is slowly 
shifting, after the realization that genes can either promote 
or suppress the growth of cells depending on the cancer type, 
underscoring the heterogeneous nature of tumor cells. To 
our knowledge, this is the first study reporting the cellular 
changes following impaired LCFA synthesis due to 17β-
HSD12 silencing and sets a basis for further understanding 
of this aspect of lipid metabolism for malignant transforma-
tion of cells.
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